Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA was delisted on the 25th of September, 2023.
57 hedge funds and large institutions have $129M invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2017 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 30 increasing their positions, 9 reducing their positions, and 6 closing their positions.
233% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 9
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
4% more funds holding
Funds holding: 55 → 57 (+2)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
8% less capital invested
Capital invested by funds: $140M → $129M (-$11.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.35M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.8M |
| 3 |
BlackRock
New York
|
+$2.59M |
| 4 |
JP Morgan Chase
New York
|
+$2.51M |
| 5 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$891K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$68.2M |
| 2 |
ACM
Ativo Capital Management
Chicago,
Illinois
|
-$1.13M |
| 3 |
Daiwa Securities Group
Tokyo,
Japan
|
-$829K |
| 4 |
Millennium Management
New York
|
-$727K |
| 5 |
Bessemer Group
Woodbridge,
New Jersey
|
-$373K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Bank of America
Charlotte,
North Carolina
| $32K | -$2.75K | -112 | -10% |
|
52
BNP Paribas Financial Markets
Paris,
France
| $29.3K | +$20.7K | +840 | +988% |
|
53
Canada Life
Winnipeg,
Manitoba, Canada
| $28K | +$22.1K | +900 | New |
|
|
AIP
54
Ameritas Investment Partners
Lincoln,
Nebraska
| $24K | +$7.47K | +304 | +69% |
|
55
Barclays
London,
United Kingdom
| $6K | +$393 | +16 | +9% |
|
56
Citigroup
New York
| $3K | -$16.4K | -668 | -88% |
|
57
Royal Bank of Canada
Toronto,
Ontario, Canada
| $2K | -$3.17K | -129 | -66% |
|
|
ACM
58
Ativo Capital Management
Chicago,
Illinois
| – | -$1.13M | -50,012 | Closed |
|
|
59
Daiwa Securities Group
Tokyo,
Japan
| – | -$829K | -36,611 | Closed |
|
|
60
Millennium Management
New York
| – | -$727K | -32,108 | Closed |
|
|
TRCT
61
Tower Research Capital (TRC)
New York
| – | -$4K | -155 | Closed |
|
62
Walleye Trading
New York
| – | -$2 | -100 | Closed |
|
|
MAM
63
Meeder Asset Management
Dublin,
Ohio
| – | -$1K | -30 | Closed |
|
RETA Hedge Fund Activity: Q2 2017 in Review
57 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) for Q2 2017, worth a combined $129M — down 8% from $140M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new RETA positions and 6 closed out — a net gain of 2 holders — while 30 added to existing stakes and 9 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $4.35M. The largest seller was Novo Holdings A/S, cutting an estimated $68.2M.
- 57 institutional investors held Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) as of Q2 2017, up from 55 in Q1 2017.
- Funds reported $129M of Reata Pharmaceuticals, Inc. Class A Common Stock stock for Q2 2017, down 8% quarter-over-quarter.
- 8 funds opened new Reata Pharmaceuticals, Inc. Class A Common Stock positions in Q2 2017 and 6 closed out, a net change of +2 holders.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock buyer in Q2 2017 was Fidelity Investments, an estimated $4.35M added.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock seller in Q2 2017 was Novo Holdings A/S, an estimated $68.2M sold.
Based on aggregated 13F filings for Q2 2017.